

ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow Series

Presentations and live Q&A to take place on Monday, August 14 and Wednesday, August 16

LOS ANGELES – ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) research and healthy aging, announced today that they will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Monday, August 14, 2023, at 12:00 p.m. ET (9:00 a.m. PT) and Wednesday, August 16, 2023 at 2:00 p.m. ET (11:00 a.m. PT). ChromaDex welcomes stakeholders, investors, and other individual followers to register and attend these live events.

The presentations will feature Rob Fried, Chief Executive Officer, and Brianna Gerber, Chief Financial Officer. Topics to be covered will include the latest investor presentation followed by a live Q&A. Investors interested in participating in either of these events will need to register using the links below. As a reminder, registration for the live events may be limited but access to the replay after the events will be on the company's Investor website. Investors may submit questions during the presentations or may email questions to InvestorRelations@ChromaDex.com or jkautz@renmarkfinancial.com ahead of the event.

REGISTER HERE:

Monday, August 14, 2023:

<https://www.renmarkfinancial.com/live-registration/renmark-virtual-non-deal-roadshow-nasdaq-cdxc-2023-08-14-120000>

Wednesday, August 16, 2023:

<https://www.renmarkfinancial.com/live-registration/renmark-virtual-non-deal-roadshow-nasdaq-cdxc-2023-08-16-140000>

- ***To ensure smooth connectivity, please access this link using the latest version of Google Chrome.***

About ChromaDex:

ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex's patent portfolio. ChromaDex maintains a website at www.chromadex.com to

which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20230807189001/en/>

ChromaDex Media Contact:

Kendall Knysch, Director of Media Relations

310-388-6706 ext. 689

kendall.knysch@chromadex.com

ChromaDex Investor Relations Contact:

+1 (949) 356-1620

InvestorRelations@ChromaDex.com

Renmark Financial Communications Inc.

James R. Kautz: jkautz@renmarkfinancial.com

Tel.: (416) 644-2020 or (212) 812-7680

www.renmarkfinancial.com